Similarly, a multicenter, open-label phase II trial aimed to ascertain the anti-tumor activity of sunitinib malate, an oral multi-TKI targeting colony stimulating factor receptor (CSFR), VEGFR-1, -2, and -3, FMS related receptor tyrosine kinase 3 (FLT3), c-Kit, PDGFR-α, and -β, among patients with advanced solid metastatic breast tumors who had previously undergone anthracycline and taxane treatment. The gene discussed is KIT; the disease is neoplasm.